NASDAQ:ATHE Alterity Therapeutics Q4 2026 TU Earnings Results & Report $3.12 0.00 (0.00%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$3.12 0.00 (-0.16%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alterity Therapeutics reported Q4 2026 TU earnings on July 30, 2026. The company reported EPS of -$0.28, while revenue was $0.31 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2026 TUReport DateJuly 30, 2026TimeBefore Market OpensConference Call DateJuly 29, 2026Conference Call8:00 PM ET Alterity Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAlterity Therapeutics Revenue ResultsActual Revenue$0.31 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Alterity Therapeutics Q4 2026 TU Earnings FAQ Did Alterity Therapeutics beat earnings estimates for Q4 2026 TU? Alterity Therapeutics (NASDAQ:ATHE) reported earnings of -$0.28 per share for Q4 2026 TU. The report was announced on Thursday, July 30, 2026. What was Alterity Therapeutics' revenue for Q4 2026 TU? Alterity Therapeutics reported revenue of $0.31 million for Q4 2026 TU. Alterity Therapeutics Earnings HeadlinesAlterity Therapeutics to Present at the Canaccord Genuity Drug and Device ConferenceOctober 9 at 7:05 AM | globenewswire.comAlterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement DisordersOctober 5, 2026 | finance.yahoo.comTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months. | Monument Traders Alliance (Ad)Alterity's ATH434 Demonstrates Slower MSA Progression In Phase 2October 5, 2026 | rttnews.comAlterity Therapeutics Reports New ATH434 Data In MSAOctober 5, 2026 | rttnews.comAlterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement DisordersOctober 5, 2026 | globenewswire.comSee More Alterity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alterity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alterity Therapeutics and other key companies, straight to your email. Email Address About Alterity TherapeuticsAlterity Therapeutics (NASDAQ:ATHE) Limited (NASDAQ: ATHE) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research centers on protein misfolding and aggregation, biological processes associated with conditions such as multiple system atrophy (MSA) and Parkinson’s disease. Alterity’s lead drug candidate is ATH434, an orally administered small molecule designed to inhibit the aggregation of alpha-synuclein, a protein implicated in several neurodegenerative disorders. The company has evaluated ATH434 in clinical studies, including research involving patients with MSA, and continues to assess its potential in synucleinopathies. Headquartered in Melbourne, Australia, Alterity conducts its development activities through international research and clinical programs. The company was formerly known as Prana Biotechnology and adopted the Alterity Therapeutics name in 2019. David Stamler serves as the company’s chief executive officer.View Alterity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
